Ribavirin reveals a lethal threshold of allowable mutation frequency for Hantaan virus

Journal of Virology

Volumn 81, Issue 21, 2007, Pages 11722-11729

  Chung, Dong Hoon ^a   Sun, Yanjie ^a   Parker, William B ^a   Arterburn, Jeffrey B ^b   Bartolucci, Al ^c   Jonsson, Colleen B ^a  

^a SOUTHERN RESEARCH INSTITUTE   (United States)

^b NEW MEXICO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; GUANOSINE TRIPHOSPHATE; INOSINATE DEHYDROGENASE; MYCOPHENOLIC ACID; RIBAVIRIN; SELENAZOFURIN; TIAZOFURIN; VIRUS RNA;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; HANTAVIRUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VIRUS GENOME; VIRUS MUTATION; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE FREQUENCY; GENOME, VIRAL; GUANOSINE TRIPHOSPHATE; HANTAAN VIRUS; MUTATION; MYCOPHENOLIC ACID; ORGANOSELENIUM COMPOUNDS; RIBAVIRIN; RIBONUCLEOSIDES; RNA, VIRAL; VERO CELLS;

HANTAAN VIRUS; RNA VIRUSES;

EID: 35448991761     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.00874-07     Document Type: Article

References (43)

1. Anderson, J. P., R. Daifuku, and L. A. Loeb. 2004. Viral error catastrophe by mutagenic nucleosides. Annu. Rev. Microbiol. 58:183-205.
2. Andrei, G., and E. De Clercq. 1993. Molecular approaches for the treatment of hemorrhagic fever virus infections. Antivir. Res. 22:45-75.
3. Bull, J. J., L. A. Meyers, and M. Lachmann. 2005. Quasispecies made simple. PLoS Comput. Biol. 1:e61.
4. Crotty, S., C. E. Cameron, and R. Andino. 2001. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc. Natl. Acad. Sci. USA 98:6895-6900.
5. Crotty, S., D. Maag, J. J. Arnold, W. Zhong, J. Y. Lau, Z. Hong, R. Andino, and C. E. Cameron. 2000. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat. Med. 6:1375-1379.
6. Daifuku, R. 2003. Stealth nucleosides: mode of action and potential use in the treatment of viral diseases. BioDrugs 17:169-177.
7. Day, C. W., D. F. Smee, J. G. Julander, V. F. Yamshchikov, R. W. Sidwell, and J. D. Morrey. 2005. Error-prone replication of West Nile virus caused by ribavirin. Antivir. Res. 67:38-45.
8. Domingo, E., C. Escarmis, E. Lazaro, and S. C. Manrubia. 2005. Quasi-species dynamics and RNA virus extinction. Virus Res. 107:129-139.
9. Eriksson, B., E. Helgstrand, N. G. Johansson, A. Larsson, A. Misiorny, J. O. Noren, L. Philipson, K. Stenberg, G. Stening, S. Stridh, and B. Oberg. 1977. Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate. Antimicrob. Agents Chemother. 11:946-951.
10. Freistadt, M. S., G. D. Meades, and C. E. Cameron. 2004. Lethal mutagens: broad-spectrum antivirale with limited potential for development of resistance? Drug Resist. Update 7:19-24.
11. Goswami, B. B., R. Crea, J. H. Van Boom, and O. K. Sharma. 1982. 2′-5′-Linked oligo(adenylic acid) and its analogs. A new class of inhibitors of mRNA methylation. J. Biol. Chem. 257:6867-6870.
12. Grande-Perez, A., E. Lazaro, P. Lowenstein, E. Domingo, and S. C. Manrubia. 2005. Suppression of viral infectivity through lethal defection. Proc. Natl. Acad. Sci. USA 102:4448-4452.
13. Grande-Perez, A., S. Sierra, M. G. Castro, E. Domingo, and P. R. Lowenstein. 2002. Molecular indetermination in the transition to error catastrophe: systematic elimination of lymphocytic choriomeningitis virus through mutagenesis does not correlate linearly with large increases in mutant spectrum complexity. Proc. Natl. Acad. Sci. USA 99:12938-12943.
14. Huggins, J. W. 1989. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev. Infect. Dis. 11(Suppl. 4):S750-S761.
15. Huggins, J. W., C. M. Hsiang, T. M. Cosgriff, M. Y. Guang, J. I. Smith, Z. O. Wu, J. W. LeDuc, Z. M. Zheng, J. M. Meegan, Q. N. Wang, et al. 1991. Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. J. Infect. Dis. 164:1119-1127.
16. Huggins, J. W., G. R. Kim, O. M. Brand, and K. T. McKee, Jr. 1986. Ribavirin therapy for Hantaan virus infection in suckling mice. J. Infect. Dis. 153:489-497.
17. Huggins, J. W., R. K. Robins, and P. G. Canonico. 1984. Synergistic antiviral effects of ribavirin and the C-nucleoside analogs tiazofurin and selenazofurin against togaviruses, bunyaviruses, and arenaviruses. Antimicrob. Agents Chemother. 26:476-480.
18. Khan, A., and A. S. Khan. 2003. Hantaviruses: a tale of two hemispheres. Panminerva Med. 45:43-51.
19. Kirsi, J. J., J. A North, P. A. McKernan, B. K. Murray, P. G. Canonico, J. W. Huggins, P. C. Srivastava, and R. K. Robins. 1983. Broad-spectrum antiviral activity of 2-beta-D-ribofuranosylselenazole- 4-carboxamide, a new antiviral agent. Antimicrob. Agents Chemother. 24:353-361.
20. Lanford, R. E., D. Chavez, B. Guerra, J. Y. Lau, Z. Hong, K. M. Brasky, and B. Beames. 2001. Ribavirin induces error-prone replication of GB virus B in primary tamarin hepatocytes. J. Virol. 75:8074-8081.
21. Lee, H. W., and G. van der Groen. 1989. Hemorrhagic fever with renal syndrome. Prog. Med. Virol. 36:62-102.
22. Leyssen, P., J. Balzarini, E. De Clercq, and J. Neyts. 2005. The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J. Virol. 79:1943-1947.
23. Loeb, L. A., J. M. Essigmann, F. Kazazi, J. Zhang, K. D. Rose, and J. I. Mullins. 1999. Lethal mutagenesis of HIV with mutagenic nucleoside analogs. Proc. Natl. Acad. Sci. USA 96:1492-1497.
24. Malinoski, F., and V. Stellar. 1981. Inhibitors of IMP dehydrogenase prevent Sindbis virus replication and reduce GTP levels in Aedes albopictus cells. Virology 110:281-289.
25. Pariente, N., S. Sierra, P. R. Lowenstein, and E. Domingo. 2001. Efficient virus extinction by combinations of a mutagen and antiviral inhibitors. J. Virol. 75:9723-9730.
26. Peters, C. J., and A S. Khan. 2002. Hantavirus pulmonary syndrome: the new American hemorrhagic fever. Clin. Infect. Dis. 34:1224-1231.
27. Schmaljohn, C., and B. Hjelle. 1997. Hantaviruses: a global disease problem. Emerg. Infect. Dis. 3:95-104.
28. Schmaljohn, C. S., and J. W. Hooper. 2001. Bunyaviridae: the viruses and their replication, p. 1581-1633. In D. M. Knipe, P. M. Howley, D. E. Griffin, R. A. Lamb, M. A. Martin, B. Roizman, and S. E. Straus (ed.), Fields virology, vol. 2. Lippincott Williams & Wilkins, Philadelphia, PA.
29. Schmaljohn, C. S., S. E. Hasty, S. A. Harrison, and J. M. Dalrymple. 1983. Characterization of Hantaan virions, the prototype virus of hemorrhagic fever with renal syndrome. J. Infect. Dis. 148:1005-1012.
30. Schmaljohn, C. S., G. B. Jennings, J. Hay, and J. M. Dalrymple. 1986. Coding strategy of the S genome segment of Hantaan virus. Virology 155:633-643.
31. Severson, W. E., C. S. Schmaljohn, A. Javadian, and C. B. Jonsson. 2003. Ribavirin causes error catastrophe during Hantaan virus replication. J. Virol. 77:481-488.
32. Sidwell, R. W., J. H. Huffman, G. P. Khare, L. B. Allen, J. T. Witkowski, and R. K. Robins. 1972. Broad-spectrum antiviral activity of virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 177:705-706.
33. Smee, D. F., M. Bray, and J. W. Huggins. 2001. Antiviral activity and mode of action studies of ribavirin and mycophenolic acid against orthopoxviruses in vitro. Antivir. Chem. Chemother. 12:327-335.
34. Smith, R. A., L. A. Loeb, and B. D. Preston. 2005. Lethal mutagenesis of HIV. Virus Res. 107:215-228.
35. Streeter, D. G., J. T. Witkowski, G. P. Khare, R. W. Sidwell, R. J. Bauer, R. K. Robins, and L. N. Simon. 1973. Mechanism of action of 1-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole), a new broad-spectrum antiviral agent. Proc. Natl. Acad. Sci. USA 70:1174-1178.
36. Stridh, S. 1983. Determination of ribonucleoside triphosphate pools in influenza A virus-infected MDCK cells. Arch. Virol. 77:223-229.
37. Summers, J., and S. Litwin. 2006. Examining the theory of error catastrophe. J. Virol. 80:20-26.
38. Sun, Y., D. H. Chung, Y. K. Chu, C. B. Jonsson, and W. B. Parker. 2007. Activity of ribavirin against Hantaan virus correlates with production of ribavirin-5′-triphosphate, not with inhibition of IMP dehydrogenase. Antimicrob. Agents Chemother. 51:84-88.
39. Takenaka, A., C. J. Gibbs, Jr., and D. C. Gajdusek. 1985. Antiviral neutralizing antibody to Hantaan virus as determined by plaque reduction technique. Arch. Virol. 84:197-206.
40. Tapia, N., G. Fernandez, M. Parera, G. Gomez-Mariano, B. Clotet, M. Quinones-Mateu, E. Domingo, and M. A. Martinez. 2005. Combination of a mutagenic agent with a reverse transcriptase inhibitor results in systematic inhibition of HIV-1 infection. Virology 338:1-8.
41. Toltzis, P., and A. S. Huang. 1986. Effect of ribavirin on macromolecular synthesis in vesicular stomatitis virus-infected cells. Antimicrob. Agents Chemother. 29:1010-1016.
42. Vignuzzi, M., J. K. Stone, and R. Andino. 2005. Ribavirin and lethal mutagenesis of poliovirus: molecular mechanisms, resistance and biological implications. Virus Res. 107:173-181.
43. Wray, S. K., B. E. Gilbert, M. W. Noall, and V. Knight. 1985. Mode of action of ribavirin: effect of nucleotide pool alterations on influenza virus ribonucleoprotein synthesis. Antivir. Res. 5:29-37.